Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash ...

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs ...

Detailed price information for Bio-Rad Laboratories (BIO-N) from The Globe and Mail including charting and trades.

Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the ...

Biodesix BDSX recently announced strategic progress in two molecular residual disease (MRD) programs to expand access to ...

Low commission rates start at $0 for U.S. listed stocks & ETFs*. Margin loan rates from 4.14% to 5.14%. Commission-free trading on stocks & ETFs. Earn $+0.06 per options contract and 5.1% APY on cash ...

Biodesix Inc. (BDSX), a diagnostic solutions company, last week reported strategic progress for two programmes regarding Molecular Residual Disease (MRD) solutions for cancer diagnosis. Biodesix is ...

(Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions ...

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com .

Sartorius stock was at EUR 260.15 after-hours at 10:24 p.m. CEST on September 29, 2026, down 0.82 percent versus the prior ...

Biodesix, Inc. announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical ...

(Nasdaq: BDSX), a leading diagnostics solutions company, announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease (MRD) solutions ...